<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285232</url>
  </required_header>
  <id_info>
    <org_study_id>Anakinra1</org_study_id>
    <nct_id>NCT01285232</nct_id>
  </id_info>
  <brief_title>The Effect of Anakinra on Insulin Secretion</brief_title>
  <official_title>The Effect of Interleukin-1 Receptor Antagonist on Insulin Secretion in Subjects With Beta Cell Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Once diabetes develops, β-cell function progressively deteriorates and therapeutic
      approaches that prevent of delay loss of β-cell function are needed in the treatment of type
      2 diabetes mellitus. Recent findings suggest that interleukin-1 (IL-1) may be involved in the
      progressive β-cell dysfunction in type 2 diabetes mellitus.

      Objective: to determine whether blocking IL-1β by recombinant human IL-1ra (anakinra)
      improves beta-cell function in subjects with β-cell dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of anakinra on insulin secretion, as derived from hyperglycemic clamps .</measure>
    <time_frame>after 4 weeks of treatment with anakinra</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect on anakinra on insulin sensitivity.</measure>
    <time_frame>after 4 week treatment of anakinra</time_frame>
    <description>Oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of anakinra on fat cell morphology and gene expression</measure>
    <time_frame>after 4 weeks of treatment with anakinra</time_frame>
    <description>Fatbiopsy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Glucose Intolerance</condition>
  <condition>Impaired Insulin Secretion</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 150 mg/day during four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo during four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>150 mg sc once daily during four weeks</description>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Kineret</other_name>
    <other_name>Interleukin1-receptor antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance assessed by oral glucose tolerance test and/or impaired
             fasting glucose ( ≥ 5.6 mmol/L) and/or HbA1c levels of 5.7-6.4%

          -  BMI &gt;25 kg/m2

          -  Age 40-70 years

        Exclusion Criteria:

          -  Known diabetes mellitus

          -  Fasting plasma glucose ≥ 7.0 mmol/L or HbA1c ≥ 6.5%

          -  Immunodeficiency or immunosuppressive treatment (including TNFα blocking agents and
             corticosteroids)

          -  Use of anti-inflammatory drugs ( including corticosteroids and non steroidal
             anti-inflammatory drugs, 100 mg or less of aspirin is allowed)

          -  Signs of current infection (fever, C-reactive protein &gt;30 mmol/L, treatment with
             antibiotics, previous or current diagnosis of tuberculosis)

          -  A history of recurrent infections

          -  Pregnancy or breastfeeding (contraception of at least 3 months before inclusion is
             required)

          -  Liver disease defined as aspartate aminotransferase or alanine aminotransferase level
             of more than three times the upper limit of normal range

          -  Renal disease defined as MDRD &lt; 60 ml/min/1.73m2

          -  Neutropenia &lt; 2x 109/L

          -  Inability to understand the nature and extent of the trial and the procedures
             required.

          -  Any medical condition that might interfere with the current study protocol

          -  Participation in a drug trial within 60 days prior to the first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.J. Tack, MD, PhD, Prof. of Diabetology</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

